Table 3.
Antiproliferative effects of the synthesized compounds.
| Growth inhibition % (±SEM) | |||||||
|---|---|---|---|---|---|---|---|
| Product | µM | HeLa | MCF7 | A2780 | |||
| 7a | 10 | 64.6 | (±1.6) | 35.7 | (±0.8) | <25 * | |
| 30 | 72.6 | (±1.9) | 37.2 | (±2.2) | 26.9 | (±2.7) | |
| 7b | 10 | 77.6 | (±0.7) | 40.8 | (±1.8) | 35.7 | (±2.2) |
| 30 | 79.2 | (±0.7) | 54.8 | (±2.6) | 36.8 | (±1.6) | |
| 7c | 10 | <25 | 41.6 | (±0.2) | 54.1 | (±2.6) | |
| 30 | 96.9 | (±1.7) | 83.7 | (±1.3) | 88.5 | (±2.1) | |
| 7d | 10 | 78.1 | (±0.6) | 47.0 | (±2.1) | 45.0 | (±2.9) |
| 30 | 78.6 | (±1.4) | 47.6 | (±1.6) | 46.8 | (±0.9) | |
| 7e | 10 | 68.7 | (±0.3) | 60.2 | (±1.9) | 30.9 | (±2.2) |
| 30 | 74.4 | (±0.7) | 62.6 | (±0.7) | 32.8 | (±1.4) | |
| 7f | 10 | <25 | <25 | 42.3 | (±2.7) | ||
| 30 | <25 | 27.1 | (±1.3) | 47.8 | (±2.1) | ||
| 7g | 10 | 61.8 | (±0.3) | 54.5 | (±1.1) | 31.4 | (±2.6) |
| 30 | 68.4 | (±0.3) | 59.3 | (±1.8) | 45.6 | (±2.4) | |
| 7h | 10 | 49.2 | (±1.3) | <25 | 42.1 | (±1.2) | |
| 30 | 66.2 | (±0.8) | 28.6 | (±2.4) | 53.2 | (±0.9) | |
| 7i | 10 | 55.7 | (±2.6) | 46.5 | (±2.1) | 31.1 | (±1.9) |
| 30 | 93.2 | (±0.8) | 63.8 | (±1.0) | 43.3 | (±2.1) | |
| 7j | 10 | 61.7 | (±0.4) | 31.3 | (±1.1) | 42.3 | (±2.6) |
| 30 | 63.6 | (±0.7) | 50.5 | (±1.1) | 47.5 | (±1.4) | |
| 11a-d | 10 | <25 | <25 | <25 | |||
| 30 | <25 | <25 | <25 | ||||
| 11e | 10 | <25 | <25 | <25 | |||
| 30 | <25 | 61.8 | (±1.7) | 72.0 | (±0.4) | ||
| Cisplatin | 10 | 42.6 | (±2.3) | 88.6 | (±0.5) | 53.0 | (±2.3) |
| 30 | 99.9 | (±0.3) | 90.2 | (±1.8) | 86.9 | (±1.2) | |
* Compounds eliciting less than 25% inhibition of proliferation were considered ineffective, and for simplicity the exact results are not given.